Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1255-1267

  Gugleta, Konstantin ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Brinzolamide; Dorzolamide; Topical carbonic anhydrase inhibitors; Visual field; Visual function

Indexed keywords

BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; LATANOPROST; PLACEBO; TIMOLOL; TRAVOPROST;

CLINICAL TRIAL; CONTRAST SENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; EYE BLOOD FLOW; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; NONHUMAN; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; REVIEW; VASODILATATION; VISION; VISUAL FIELD;

ADMINISTRATION, TOPICAL; CARBONIC ANHYDRASE INHIBITORS; GLAUCOMA; HUMANS; OCULAR HYPERTENSION; SULFONAMIDES; THIAZINES; THIOPHENES; VISUAL FIELDS;

EID: 77952471030     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003738485     Document Type: Review

References (72)

1. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science 1991;254:1178-1181
2. Graefe AV. Ueber die Iridektomie beim Glaukom und ueber den glaukomatö-sen Prozess. Arch Ophthalmol 1857;3:470
3. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505
4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-1279
5. The AGIS Investigators.The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-440
6. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-1953
7. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypoten-sive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-713
8. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-1185
9. Park HY, Lee NY, Kim JH, Park CK. Intraocular pressure lowering, change of antiapoptotic molecule expression, and neuroretinal changes by dorzolamide 2%/timolol 0.5% combination in a chronic ocular hypertension rat model. J Ocul Pharmacol Ther 2008;24:563-571
10. Zanon-Moreno V, Garcia-Medina JJ, Gallego-Pinazo R et al.Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. Eur J Ophthalmol 2009;19:565-571
11. Gasser P, Flammer J. Influence of vasospasm on visual function. Doc Ophthalmol 1987;66:3-18
12. Pillunat LE, Lang GK, Harris A. The visual response to increased ocular blood flow in normal pressure glaucoma. Surv Ophthalmol 1994;38 (Suppl.):S139-47
13. Sugrue M, Harris A, Adamsons I. Dorzolamide hydrochloride: a topically active carbonic anhydrase inhibitor for the treatment of glaucoma. Drugs Today 1997;33:283-298
14. Schmitz K, Banditt P, Motschmann M, et al. Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans. Invest Ophthalmol Vis Sci 1999;40:1621-1624
15. Rassam SM, Patel V, Kohner EM. The effect of acetazolamide on the retinal circulation. Eye 1993;7:697-702
16. Taki K, Kato H, Endo S, et al. Cascade of acetazolamide-induced vasodilata-tion. Res Commun Mol Pathol Pharmacol 1999;103:240-248
17. Friberg L, Kastrup J, Rizzi D, et al. Cerebral blood flow and end-tidal pCO2 during prolonged acetazolamide treatment in humans. Am J Physiol 1990; 258:H954-9
18. Josefsson A, Sigurdsson SB, Bang K, et al. Dorzolamide induces vasodilata-tion in isolated pre-contracted bovine retinal arteries. Exp Eye Res 2004; 78:215-221
19. Torring MS, Holmgaard K, Hessellund A, et al. The vasodilating effect of acetazolamide and dorzolamide involves mechanisms other than carbonic anhydrase inhibition. Invest Ophthalmol Vis Sci 2009;50:345-351
20. Friedman E, Chandra SR. Choroidal blood flow. 3. Effects of oxygen and carbon dioxide. Arch Ophthalmol 1972;87:70-71
21. Riva CE, Cranstoun SD, Grunwald JE, et al. Choroidal blood flow in the foveal region of the human ocular fundus. Invest Ophthalmol Vis Sci 1994; 35:4273-4281
22. Schmetterer L, Wolzt M, Lexer F, et al. The effect of hyperoxia and hyper-capnia on fundus pulsations in the macular and optic disc region in healthy young men. Exp Eye Res 1995;61:685-690
23. Hageman GS, Zhu XL, Waheed A, et al. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc Natl Acad Sci USA 1991; 88:2716-2720
24. Sender S, Gros G, Waheed A, et al. Immunohistochemical localization of carbonic anhydrase IV in capillaries of rat and human skeletal muscle. J Histochem Cytochem 1994;42:1229-1236
25. Kehler AK, Holmgaard K, Hessellund A, et al. Variable involvement of the perivascular retinal tissue in carbonic anhydrase inhibitor induced relaxation of porcine retinal arterioles in vitro. Invest Ophthalmol Vis Sci 2007;48: 4688-4693
26. Inoue J, Oka M, Aoyama Y, et al. Effects of dorzolamide hydrochloride on ocular tissues. J Ocul Pharmacol Ther 2004;20:1-13
27. Nagelhus EA, Mathiisen TM, Bateman AC, et al. Carbonic anhydrase XIV is enriched in specific membrane domains of retinal pigment epithelium, Muller cells, and astrocytes. Proc Natl Acad Sci USA 2005;102:8030-8035
28. Olander KW, Galet VA, Jia G, et al. Relationship between visual field severity and response to fixed combination dorzolamide/timolol or timolol alone. J Ocul Pharmacol Ther 2009;25:357-364
29. Kaup M, Plange N, Niegel M, et al. Effects of brinzolamide on ocular haemo-dynamics in healthy volunteers. Br J Ophthalmol 2004;88:257-262
30. Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366-375 (Pubitemid 40312486)
31. Strahlman E, Tipping R, Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group. Am J Ophthalmol 1996;122: 183-194
32. Quigley HA. European Glaucoma Prevention Study. Ophthalmology 2005;112: 1642-1643
33. Parrish 2nd RK. The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: why do two studies have different results? Curr Opin Ophthalmol 2006;17:138-141
34. Martinez A, Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retro-bulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharmacol Ther 2009;25:239-248
35. Martinez A, Sanchez M. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. Acta Ophthalmol 2009 Oct [Epub ahead of print]
36. Flammer J, Haefliger IO, Orgul S, et al. Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma 1999;8:212-219
37. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-720
38. Siesky B, Harris A, Brizendine E, et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol 2009;54:33-46
39. Martinez A, Sanchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study. Clin Ther 2008;30:1120-1134
40. Asman P, Heijl A. Glaucoma Hemifield Test. Automated visual field evaluation. Arch Ophthalmol 1992;110:812-819
41. Chen PP, Bhandari A. Fellow eye prognosis in patients with severe visual field loss in 1 eye from chronic open-angle glaucoma. Arch Ophthalmol 2000; 118:473-478
42. Nouri-Mahdavi K, Hoffman D, Gaasterland D, et al. Prediction of visual field progression in glaucoma. Invest Ophthalmol Vis Sci 2004;45:4346-4351
43. O'Brien C, Schwartz B, Takamoto T, et al. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol 1991;111: 491-500
44. Katz J, Gilbert D, Quigley HA, et al. Estimating progression of visual field loss in glaucoma. Ophthalmology 1997;104:1017-1025
45. Dong J, Chihara E. Slope analysis of the optic disc in eyes with ocular hypertension and early normal tension glaucoma by confocal scanning laser ophthalmoscope. Br J Ophthalmol 2001;85:56-62
46. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-1972
47. Heijl A, Bengtsson B, Chauhan BC, et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology 2008;115:1557-1565
48. Polska E, Kircher K, Ehrlich P, et al. RI in central retinal artery as assessed by CDI does not correspond to retinal vascular resistance. Am J Physiol Heart Circ Physiol 2001;280:H1442-7
49. Galassi F, Sodi A, Ucci F, et al. Ocular hemodynamics and glaucoma prognosis: a color Doppler imaging study. Arch Ophthalmol 2003;121: 1711-1715
50. Satilmis M, Orgul S, Doubler B, Flammer J. Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. Am J Ophthalmol 2003;135:664-669
51. Zeitz O, Galambos P, Wagenfeld L, et al. Glaucoma progression is associated with decreased blood flow velocities in the short posterior ciliary artery. Br J Ophthalmol 2006;90:1245-1248
52. Martinez A, Sanchez M. Predictive value of colour Doppler imaging in a prospective study of visual field progression in primary open-angle glaucoma. Acta Ophthalmol Scand 2005;83:716-722
53. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-135
54. Stewart WC, Kruft B, Nelson LA, et al. Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union. Eur J Ophthalmol 2009;19:588-593
55. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retinal Eye Res 2000;19:87-112
56. Stams T, Chen Y, Boriack-Sjodin PA, et al. Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brin-zolamide: molecular basis of isozyme-drug discrimination. Protein Sci 1998;7:556-563
57. Siesky B, Harris A, Cantor LB, et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular micro-circulation in patients with primary open-angle glaucoma. Br J Ophthalmol 2008;92:500-504
58. Costagliola C, Campa C, Parmeggiani F, et al. Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol. Br J Clin Pharmacol 2007; 63:376-379
59. Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dor-zolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia 2005;49:39-45
60. Fuchsjä ger-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005;89:1293-1297
61. Fuchsjä ger-Mayrl G, Georgopoulos M, Hommer A, et al. Effect of dorzolamide and timolol on ocular pressure-blood flow relationship in patients with primary open angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 2010;51:1289-1296
62. Bernd AS, Pillunat LE, Bohm AG, et al. [Ocular hemodynamics and visual field in glaucoma treated with dorzolamide]. Ophthalmologe 2001;98:451-455
63. Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1999;106:1-9
64. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (Cosopt) versus 0.005% (Xalatan) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82:42-48
65. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995;113:1009-1016
66. Heijl A, Strahlman E, Sverrisson T, et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology 1997;104:137-142
67. Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzola-mide 1% and timolol 0.5%. Ophthalmology 2008;115:1728-1734
68. Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 2008;24:1435-1442
69. Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 2005;21:503-508
70. Michaud JE, Friren B. Comparison of topical brinzolamide 1% and dorzola-mide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:235-243
71. Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 2000;44(Suppl. 2): S163-8
72. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126:400-408